Patent Oppositions in peptide drugs industry

Explore the competitive field of peptide drugs where companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top companies filing and facing patent oppositions, and the most recent patents under dispute. Stay informed on patent activity in peptide drugs technology and learn how to protect your intellectual property.

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Explore the top law firms that have filed the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the peptide drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the peptide drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Feb 12, 2026
Patent NumberTitleApplicantOpposition DateOpposition Name
Treatment Of HypoparathyroidismENTERA BIODec 29, 2025KRAUS & LEDERER PARTGMBB
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKDec 24, 2025POLPHARMA
Antibody Compositions And Methods Of Use ThereofHALOZYMEDec 22, 2025PAJARO
Antibody Compositions And Methods Of Use ThereofBRISTOL MYERS SQUIBBDec 19, 2025CAMULON
High Protein Enteral Tube Feed For Icu PatientsFRESENIUS KABI DEUTSCHLANDDec 16, 2025NESTLE
A Myostatin Pathway Inhibitor In Combination With A Glp-1 Pathway Activator For Use In Treating Metabolic DisordersSCHOLAR ROCKDec 3, 2025MARGARET DIXON
Methods And Compositions For Rna-Directed Target Dna Modification And For Rna-Directed Modulation Of TranscriptionUNIVERSITT WIENNov 26, 2025POHLMAN
Methods And Compositions For Rna-Directed Target Dna Modification And For Rna-Directed Modulation Of TranscriptionUNIVERSITT WIENNov 25, 2025HGF
Use Of Long-Acting Glp-1 PeptidesNOVO NORDISKNov 20, 2025GALENICUM HEALTH SLU
Combination Of Collagen Peptide And Whey Protein For Use In A Condition Of The Skeletal TissueROUSSELOTNov 12, 2025COMPAGNIE GERVAIS DANONE

To stay ahead in the competitive peptide drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the peptide drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Feb 12, 2026
Patent NumberPublication DateTitleApplicantTotal Oppositions
Nov 21, 2018Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA12
Dec 18, 2024Pharmaceutical Composition, Methods For Treating And Uses ThereofBOEHRINGER INGELHEIM11
Dec 11, 2019Methods Of Treating Hepatic EncephalopathySALIX PHARMACEUTICALS8
Nov 3, 2021SyringeNOVARTIS8
Feb 7, 2024Glp-1 Compositions And Uses ThereofNOVO NORDISK8
Aug 10, 2022Semaglutide In Cardiovascular ConditionsNOVO NORDISK8
Feb 7, 2024Methods For Treating Severe Atopic Dermatitis By Administering An Il-4R InhibitorREGENERON PHARMACEUTICALS7
Sep 13, 2023Compositions Comprising A Delivery Agent And Preparation ThereofNOVO NORDISK7
Aug 7, 2019Methods To Mobilize Progenitor/Stem CellsGENZYME7
Apr 14, 2021Tablet Formulation Comprising A Peptide And A Delivery AgentNOVO NORDISK7